It is an impurity present in Tofacitinib, Tofacitinib is an inhibitor of Janus kinases is a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function, prevent the body from responding to cytokine signals. by that prevents the phosphorylation and activation of STATs, the JAK-STAT signaling pathway is the transcription of cells involved in hematopoiesis and immune cell function. which works by inhibiting the JAK-STAT pathway to decrease the inflammatory response, there is evidence to suggest that it may achieve efficacy via other pathways as well.
Additional information on (3R | 4R)-1-Nitroso Tofacitinib
N-methyl-N-((3R, 4R)-4-methyl-1-nitrosopiperidin-3-yl)-5H-pyrrolo[2, 3-d]pyrimidin-4-amine
J. Kucharz, E., Stajszczyk, M., Kotulska-Kucharz, A., Batko, B., Brzosko, M., Jeka, S., … Wiland, P. (2018). Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the Polish Society for Rheumatology. Reumatologia/Rheumatology, 56(4), 203–211. https://doi.org/10.5114/reum.2018.77971
Other products related to tofacitinib
|CAS No.||Name of Impurity||Parent Drug||Catalogue No.|